Last updated on February 2016

A Phase 3, double blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer’s disease


Brief description of study

A Phase 3, double blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer’s disease

Detailed Study Description

The primary objectives of this study are to assess the effects of RVT-101 versus placebo as adjuncts to stable donepezil therapy on cognitive function as measured by the Alzheimer’s Disease Assessment Scale - Cognitive Subscale 11 items (ADAS-Cog-11) after 24 weeks of treatment AND on activities of daily living as measured by the Alzheimer’s Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) scale after 24 weeks of treatment.

Clinical Study Identifier: TX142752

Contact Investigators or Research Sites near you

Start Over
Sorry. There are no research Sites conducting this study in the radius provided. ( View all Sites )